Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks
Glad I held to see this bought out at a decent price
UVIC: cash merger of Unilens Vision, Inc. (UVIC) where shareholders will receive $12.75 per share.
FINRA deleted symbol:
http://otce.finra.org/DLDeletions
hi 10 Bagger, great to see Unilens getting some attention on these boards!
07/29/2011 3.06 3.06 3.06 3.06 1,900
07/28/2011 3.05 - - 3.05 0
07/27/2011 3.05 - - 3.05 0
07/26/2011 3.05 3.05 3.05 3.05 2,000
07/25/2011 3.05 - - 3.05 0
07/22/2011 3.05 - - 3.05 0
07/21/2011 3.05 3.05 3.05 3.05 500
07/20/2011 3.00 3.00 3.00 3.00 2,300
07/19/2011 3.50 - - 3.50 0
07/18/2011 3.50 - - 3.50 0
07/15/2011 3.50 - - 3.50 0
07/14/2011 3.00 3.50 2.70 3.50 550
07/13/2011 2.90 - - 2.90 0
07/12/2011 2.98 2.98 2.90 2.90 5,000
07/11/2011 3.50 - - 3.50 0
07/08/2011 3.50 - - 3.50 0
07/07/2011 3.50 - - 3.50 0
07/06/2011 3.50 3.50 3.50 3.50 936
07/05/2011 4.16 4.16 4.16 4.16 300
07/01/2011 2.95 - - 2.95 0
06/30/2011 3.05 3.05 2.63 2.95 6,100
06/29/2011 3.50 3.50 3.05 3.05 1,200
06/28/2011 3.65 - - 3.65 0
06/27/2011 3.65 3.65 3.65 3.65 600
06/24/2011 3.25 - - 3.25 0
06/23/2011 3.25 - - 3.25 0
06/22/2011 3.25 - - 3.25 0
06/21/2011 3.25 - - 3.25 0
06/20/2011 3.25 3.25 3.25 3.25 400
06/17/2011 3.25 3.25 3.25 3.25 1,000
06/16/2011 3.69 - - 3.69 0
06/15/2011 3.69 - - 3.69 0
06/14/2011 3.69 - - 3.69 0
06/13/2011 3.69 - - 3.69 0
06/10/2011 3.69 - - 3.69 0
06/09/2011 3.70 3.70 3.69 3.69 3,089
06/08/2011 3.10 3.10 3.10 3.10 1,000
06/07/2011 3.24 3.25 3.20 3.20 6,500
06/06/2011 2.66 3.01 2.66 3.00 11,500
06/03/2011 3.00 3.00 3.00 3.00 10,125
06/02/2011 3.50 - - 3.50 0
06/01/2011 3.07 3.50 3.07 3.50 5,350
05/31/2011 3.50 3.60 3.50 3.60 4,150
05/27/2011 3.50 3.50 3.50 3.50 857
05/26/2011 3.50 - - 3.50 0
05/25/2011 2.56 3.50 2.56 3.50 1,779
05/24/2011 3.50 - - 3.50 0
05/23/2011 3.50 3.55 3.50 3.50 10,700
05/20/2011 3.50 3.50 3.35 3.50 10,800
05/19/2011 3.25 3.35 3.25 3.35 1,700
05/18/2011 3.25 3.25 3.25 3.25 5,300
05/17/2011 3.77 3.77 2.56 3.50 4,550
05/16/2011 3.85 3.98 3.77 3.85 4,600
05/13/2011 3.80 3.80 3.80 3.80 2,700
05/12/2011 4.00 4.00 3.80 3.80 5,546
05/11/2011 4.05 - - 4.05 0
05/10/2011 4.10 4.10 4.10 4.05 500
05/09/2011 4.10 4.10 4.10 4.10 10,200
05/06/2011 4.10 - - 4.10 0
05/05/2011 4.10 4.10 4.10 4.10 1,000
05/04/2011 4.10 - - 4.10 0
05/03/2011 4.10 4.10 4.10 4.10 3,300
05/02/2011 4.10 4.10 4.10 4.10 1,000
04/29/2011 4.25 - - 4.25 0
04/28/2011 4.25 4.25 4.25 4.25 4,193
04/27/2011 4.20 - - 4.20 0
04/26/2011 4.20 4.20 4.20 4.20 950
04/25/2011 4.25 4.25 4.25 4.25 11,800
04/21/2011 4.40 - - 4.40 0
04/20/2011 4.10 4.40 4.10 4.40 2,700
04/19/2011 4.22 4.22 4.22 4.22 925
04/18/2011 4.25 - - 4.25 0
04/15/2011 4.25 4.25 4.25 4.25 4,600
04/14/2011 4.25 - - 4.25 0
04/13/2011 4.25 - - 4.25 0
04/12/2011 4.25 4.25 4.25 4.25 1,200
04/11/2011 4.25 4.25 4.25 4.25 2,500
04/08/2011 4.15 4.20 4.15 4.20 1,922
04/07/2011 4.10 4.10 4.08 4.08 1,400
04/06/2011 3.13 4.25 3.13 4.22 10,370
04/05/2011 4.10 4.20 4.10 4.20 5,195
04/04/2011 4.38 4.38 4.00 4.10 41,034
04/01/2011 4.60 - - 4.60 0
03/31/2011 4.60 - - 4.60 0
03/30/2011 4.60 4.60 4.60 4.60 100
03/29/2011 4.45 4.79 4.45 4.60 7,334
03/28/2011 4.65 4.65 4.65 4.65 3,700
03/25/2011 4.40 4.40 4.40 4.40 500
03/24/2011 4.50 4.79 4.50 4.79 1,140
03/23/2011 4.65 4.66 4.65 4.66 1,800
03/22/2011 4.79 4.79 4.79 4.79 212
03/21/2011 4.70 4.70 4.70 4.70 200
03/18/2011 4.89 4.89 4.80 4.80 2,358
03/17/2011 4.60 - - 4.60 0
03/16/2011 4.60 4.60 4.60 4.60 900
03/15/2011 4.40 4.60 4.40 4.55 10,500
03/14/2011 4.65 - - 4.65 0
03/11/2011 4.65 4.85 4.65 4.65 9,600
03/10/2011 4.91 - - 4.91 0
03/09/2011 4.90 4.91 4.90 4.91 1,265
03/08/2011 4.43 4.43 4.43 4.43 315
03/07/2011 4.65 4.76 4.65 4.65 3,888
03/04/2011 4.65 - - 4.65 0
03/03/2011 4.41 4.65 4.41 4.65 562
03/02/2011 4.75 4.75 4.65 4.65 1,800
03/01/2011 4.60 - - 4.60 0
02/28/2011 4.60 4.60 4.60 4.60 347
02/25/2011 4.50 4.50 4.50 4.50 335
02/24/2011 4.60 - - 4.60 0
02/23/2011 4.60 4.60 4.60 4.60 2,935
02/22/2011 4.50 - - 4.50 0
02/18/2011 4.50 - - 4.50 0
02/17/2011 4.50 4.50 4.50 4.50 1,100
02/16/2011 4.50 4.60 4.45 4.60 2,400
02/15/2011 4.34 4.50 4.34 4.50 800
02/14/2011 4.69 4.69 4.55 4.55 2,200
02/11/2011 4.73 4.73 4.70 4.70 3,400
02/10/2011 4.71 4.71 4.71 4.71 500
02/09/2011 4.16 4.73 4.16 4.72 2,486
02/08/2011 4.50 4.60 4.30 4.50 26,700
02/07/2011 4.336 - - 4.336 0
02/04/2011 4.89 4.89 4.336 4.336 700
02/03/2011 4.40 - - 4.40 0
02/02/2011 4.40 4.40 4.40 4.40 600
02/01/2011 4.40 4.40 4.40 4.40 1,000
01/31/2011 4.45 - - 4.45 0
01/28/2011 4.45 - - 4.45 0
01/27/2011 4.72 4.72 4.266 4.45 3,520
01/26/2011 4.50 4.74 4.50 4.74 3,600
01/25/2011 4.58 - - 4.58 0
01/24/2011 4.58 4.58 4.58 4.58 1,500
01/21/2011 4.74 4.74 4.74 4.74 400
01/20/2011 4.571 - - 4.571 0
01/19/2011 4.571 - - 4.571 0
01/18/2011 4.587 4.60 4.57 4.571 11,850
01/14/2011 4.41 4.41 4.41 4.41 150
01/13/2011 4.50 - - 4.50 0
01/12/2011 4.50 - - 4.50 0
01/11/2011 4.50 - - 4.50 0
01/10/2011 4.50 4.50 4.50 4.50 500
01/07/2011 4.50 - - 4.50 0
01/06/2011 4.50 - - 4.50 0
01/05/2011 4.37 4.50 4.37 4.50 4,500
01/04/2011 4.36 - - 4.36 0
01/03/2011 4.36 4.36 4.36 4.36 500
12/31/2010 4.40 4.40 4.35 4.35 2,325
UVIC.. $3.07 Dividend..
Unilens Vision, Inc. (UVIC) Declares $0.045 Quarterly Dividend; 5.9% Yield
Street Insider - Aug 01 08:34 EDT
Alert hits:all med (/u
Company Symbols: OTC-PINK:UVIC, TorontoVE:UVI
Unilens Vision, Inc. (: UVIC) declared a quarterly dividend of $0.045 per share, or $0.18 annualized.
The dividend will be payable on August 26, 2011, to stockholders of record on August 12, 2011, with an ex-dividend date of August 10, 2011.
The annual yield on the dividend is 5.9 percent.
Unilens Vision Reports Higher Third Quarter Sales and Net Income, as Custom Soft Lens Sales Rise 34% in Response to Successful New Product Launches
Marketwire - May 16 08:28 EDT
Alert hits:(/u
Company Symbols: OTC-PINK:UVIC, TorontoVE:UVI, ACORN:A.1203525542, ACORN:A.750141051
Diluted EPS Increase 30% on Fewer Diluted Shares Outstanding
LARGO, FL -- (MARKET WIRE) -- 05/16/11 -- Unilens Vision Inc. (OTCBB: UVIC) (TSX-V: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2011.
For the three months ended March 31, 2011 (third quarter of FY2011), total revenue including royalty income declined 4.4% to approximately $2.2 million, compared with approximately $2.3 million in the three months ended March 31, 2010. Sales of the Company's specialty contact lenses were relatively unchanged at approximately $1.5 million in the third quarter of each fiscal year. Royalty income decreased 14.0% to approximately $0.6 million in the most recent quarter, compared with approximately $0.7 million in the prior-year quarter. Declines in sales of disposable contact lenses and replacement/other lens categories were more than offset by increased sales of the Company's custom soft lenses during the quarter. The Company believes that the continued impact of a soft U.S. economy upon the specialty contact lens market and a competitor's new disposable multifocal lenses and rebate programs, were primarily responsible for softness in sales and royalty income in the third quarter of FY2011, when compared with the year-earlier period.
Pretax income decreased 1.9% to $442,177 in the third quarter of FY2011, compared with $450,559 in the quarter ended March 31, 2010. The modest decline in pretax income was primarily attributable to lower royalty income and gross profits, largely offset by a 12.9% decrease in selling, general and administrative (SG&A) expenses.
The Company reported net income of $296,792 in the most recent quarter, for an increase of 7.7% when compared with net income of $275,569 in last year's third fiscal quarter. The Company earned $0.13 per diluted share in the third quarter of FY2011, which represented an increase of 30.0% versus earnings of $0.10 per diluted share in the third quarter of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the FY2011 third quarter, versus 2,855,684 diluted shares in the prior-year quarter. The 17% decrease in weighted average diluted shares outstanding resulted from the Company's repurchase of a large block of common stock from its previously largest shareholder on January 20, 2010.
"I am very pleased to report that sales in our custom soft lens category increased approximately 34% in the third fiscal quarter, reflecting our continued success in converting customers from the C-Vue Advanced Toric Multifocal lens free trial program into purchasers of revenue-generating boxes, and initial sales of our recently launched C-VUE Advanced® HydraVUE™ line of completely customizable silicone hydrogel contact lenses for monthly replacement," observed Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "Increased sales of these custom soft lenses more than offset declines in our disposable lens category and sales of replacement and other lenses, thereby allowing us to report a modest total sales increase in the most recent quarter. We believe the decline in royalty income from Bausch & Lomb during the third quarter continued to reflect new competitive product offerings and associated rebate programs in the disposable multifocal lens product category."
"Looking forward, we continue to believe that Unilens can realize significant sales growth by targeting the specialty segment of the contact lens market in order to benefit from demographic trends in America, and by working closely with independent eye care practitioners to develop sales and marketing strategies that can increase patient retention and practice profitability," continued Pecora. "As the 40 and over presbyopic population continues to grow faster than the population as a whole, the demand for custom and other specialty contact lenses should increase at an accelerating pace, as well," concluded Pecora.
For the nine months ended March 31, 2011, total revenue including royalty income decreased 6.1% to approximately $6.5 million, compared with approximately $6.9 million in the first nine months of FY2010. The decrease in revenue was primarily due to a 3.7% decline in sales of the Company's various types of specialty contact lenses and an 11.0% decline in royalty income.
Pretax income decreased 23.2% to $1,456,000 in the nine months ended March 31, 2011, compared with $1,895,360 in the prior-year period. The decrease in pretax income was primarily attributable to lower sales, royalty income and gross profit, along with an increase in interest expense related to the Company's loan with Regions Bank, partly offset by a reduction in SG&A expenses.
The Company reported net income of $978,878 for the first nine months of FY2011, a decrease of 18.1% when compared with net income of $1,194,965 in the corresponding period of the previous fiscal year. The Company earned $0.41 per diluted share in the first nine months of FY2011, which represented an increase of 36.7% when compared with earnings of $0.30 per diluted share in the first nine months of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the nine months ended March 31, 2011, versus 3,998,122 diluted shares in the prior-year period.
The Company recently declared its 19th consecutive quarterly cash dividend, in the amount of $0.045 per share of common stock outstanding. The amount and frequency of future dividends will depend upon earnings, cash flow, and other aspects of the Company's business as determined and declared by the Board of Directors.
About Unilens Vision Inc. - "The Independent Eye Care Professionals' Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida and its wholly owned subsidiary Unilens Vision Sciences Inc. develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
UNILENS VISION INC.
THIRD QUARTER - FISCAL 2011
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
(All figures in U.S. Dollars)
RESULTS OF OPERATIONS
Three Months Three Months Nine Months Nine Months
Ended Ended Ended Ended
March March March March
31, 2011 31, 2010 31, 2011 31, 2010
----------- ----------- ----------- -----------
Revenues:
Sales $ 1,539,555 $ 1,535,454 $ 4,462,223 $ 4,633,666
Royalty income 631,893 734,803 2,007,702 2,253,865
----------- ----------- ----------- -----------
Total revenues 2,171,448 2,270,257 6,469,925 6,887,531
----------- ----------- ----------- -----------
Operating costs and
expenses:
Cost of sales 928,612 912,581 2,704,456 2,717,169
Expenses 720,883 827,865 2,088,758 2,204,063
----------- ----------- ----------- -----------
Total operating costs
and expenses 1,649,495 1,740,446 4,793,214 4,921,232
----------- ----------- ----------- -----------
Income from operations 521,953 529,811 1,676,711 1,966,299
----------- ----------- ----------- -----------
Other non-operating
items:
Other expense (13,734) (16,059) (12,289) (15,236)
Remeasurement loss - (3,398) - (1,575)
Interest expense (66,042) (59,795) (208,422) (54,128)
----------- ----------- ----------- -----------
Total other
non-operating items (79,776) (79,252) (220,711) (70,939)
----------- ----------- ----------- -----------
Income before income
tax expense 442,177 450,559 1,456,000 1,895,360
Income tax expense 145,385 174,990 477,122 700,395
----------- ----------- ----------- -----------
Net income for the
period $ 296,792 $ 275,569 $ 978,878 $ 1,194,965
=========== =========== =========== ===========
Net income per common
share:
Basic $ 0.13 $ 0.10 $ 0.41 $ 0.30
Diluted $ 0.13 $ 0.10 $ 0.41 $ 0.30
Weighted average shares
outstanding 2,369,354 2,855,684 2,369,354 3,998,122
=========== =========== =========== ===========
CASH FLOWS
----------- ----------- ----------- -----------
Provided (used) by:
Operating activities $ 1,095,306 $ 2,122,312
Investing activities (140,757) 477,219
Financing activities (1,552,288) (2,691,349)
----------- ----------- ----------- -----------
(Decrease) increase in
cash $ (597,739) $ (91,818)
=========== =========== =========== ===========
June 30, March 31, March 31,
BALANCE SHEET 2010 2011 2010
----------- ----------- ----------- -----------
Cash and cash
equivalents $ 1,080,540 $ 482,801 $ 1,085,233
Total assets 4,467,338 3,858,454 4,552,449
Current liabilities 2,519,513 1,815,126 2,444,815
Total liabilities 6,819,513 5,884,265 7,044,815
Stockholders' (deficit)
equity $(2,352,175) $(2,025,811) $(2,492,366)
=========== =========== =========== ===========
Unilens Vision Inc. Declares Quarterly Cash Dividend of $0.045 Per Share
PR Newswire - May 02 11:28 EDT
Alert hits:(/u
Company Symbols: TorontoVE:UVI, OTC-PINK:UVIC
LARGO, Fla., May 2, 2011 /PRNewswire/ -- The Unilens Vision Inc. (OTCBB: UVIC) (OTCQB: UVIC) (TSX Venture Exchange: UVI) Board of Directors today declared a quarterly cash dividend of $0.045 per common share, payable May 27, 2011 to stockholders of record at the close of business on May 13, 2011.
About Unilens Vision Inc. – "The Eye Care Professionals Specialty Contact Lens Company"
Established in 1989, Unilens Vision Inc., a Delaware corporation, through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, and its wholly owned subsidiary Unilens Vision Sciences Inc. develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on OTC Bulletin Board and OTCQB exchanges under the symbol "UVIC" as well as the Canadian TSX Venture Exchange under the symbol "UVI."
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531 or via email at len.barker@unilens.com
or
RJ Falkner & Company, Inc., Investor Relations Counsel at (800) 377-9893 or via email at info@rjfalkner.com
SOURCE Unilens Vision Inc.
Unilens Vision Inc. Announces Amendment to Term Loan Facility, Capital Equipment Financing and Reduction in Quarterly Cash Dividend
Marketwire - Apr 04 08:28 EDT
Alert hits:(/u
Company Symbols: TorontoVE:UVI, OTC-PINK:UVIC
LARGO, FL -- (MARKET WIRE) -- 04/04/11 -- Unilens Vision Inc. (OTCBB: UVIC) (OTCQB: UVIC) (TSX-V: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today announced an amendment to its term loan facility with Regions Bank and a reduction to its quarterly cash dividend.
The amendment to the term loan facility reduces the Company's minimum monthly principal repayment from $100,000 to $54,762, retaining the January 2015 expiration date, at which time a final balloon payment will be due, although additional quarterly principal payments (not to exceed the original amortization in the aggregate) will be payable to the extent the Company generates cash flow in excess of certain specified amounts. In addition, Regions Bank is providing the Company with a new seven-year credit facility of up to $500,000 for capital equipment financing.
In conjunction with the amendment to the term loan facility, the Company's Board of Directors has voted to reduce the quarterly cash dividend payable to common shareholders to $0.045 per share from the previous quarterly cash dividend rate of $0.09 per share.
"We are very pleased to announce the amendment to our term loan facility with Regions Bank and the bank's agreement to extend the Company up to $500,000 in credit for capital equipment financing," stated Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "When combined with the reduction in our quarterly cash dividend, our monthly cash flows from operations will improve significantly, thereby allowing us to expand our manufacturing capabilities and further develop our sales and marketing initiatives in support of the growth that we anticipate from our Custom lens category sales in coming years. As the 40 and over presbyopic population continues to grow faster than the population as a whole, we believe the ability to satisfy the increasing demand for existing and future toric multifocal and multifocal contact lens product offerings will create substantial value for our shareholders. Although we considered it necessary to reduce the cash dividend in order to achieve these strategic objectives, the new quarterly cash dividend rate still provides a healthy annualized yield of 3.9%, based upon the most recent closing stock price of $4.60 per share."
About Unilens Vision Inc. -- "The Eye Care Professionals Specialty Contact Lens Company"
Established in 1989, Unilens Vision Inc., a Delaware corporation, through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, and its wholly owned subsidiary Unilens Vision Sciences Inc. develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on OTC Bulletin Board and OTCQB exchanges under the symbol "UVIC" as well as the Canadian TSX Venture Exchange under the symbol "UVI."
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker
CFO
Unilens Vision Inc.
(727) 544-2531
len.barker@unilens.com
or
RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
info@rjfalkner.com
Unilens Vision Reports Second Quarter Operating Results, Including 67% Increase in Diluted EPS ($0.15 vs. $0.09) on Fewer Shares Outstanding
Marketwire - Feb 14 15:17 EDT
Alert hits:(/u
Company Symbols: NASDAQ-OTCBB:UVIC, TorontoVE:UVI
Company's Emphasis Upon Specialty Contact Lenses Anticipates Above-Average Growth of America's Presbyopic Population
LARGO, FL -- (MARKET WIRE) -- 02/14/11 -- Unilens Vision Inc. (OTCBB: UVIC) (TSX-V: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2011.
For the three months ended December 31, 2010 (second quarter of FY2011), total revenue including royalty income declined 2.6% to approximately $2.1 million, compared with approximately $2.2 million in the three months ended December 31, 2009. Sales of the Company's specialty contact lenses declined 1.5%, while royalty income decreased 4.8%, when compared with the prior-year quarter. The Company believes that the continued impact of a soft U.S. economy upon the specialty contact lens market and new product offerings by competitors were the primary reasons for lower sales and royalty income in the second quarter of FY2011, when compared with the year-earlier quarter.
Pretax income decreased 20.6% to $519,659 in the second quarter of FY2011, compared with $654,071 in the quarter ended December 31, 2009. The reduction in pretax income was primarily attributable to lower sales and royalty income and an increase in interest expense related to the Company's loan with Regions Bank, which financed the repurchase of 48% of the Company's previously outstanding shares in January 2010; partially offset by lower administrative and sales and marketing ("SG&A") expenses.
The Company reported net income of $350,237 in the most recent quarter, a decrease of 17.7% when compared with net income of $425,308 in last year's second fiscal quarter. The Company earned $0.15 per diluted share in the second quarter of FY2011, which represented an increase of 66.7% versus earnings of $0.09 per diluted share in the second quarter of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the FY2011 second quarter, versus 4,557,852 diluted shares in the prior-year quarter. The 48% decrease in weighted average diluted shares outstanding resulted from the Company's repurchase of 2,188,861 outstanding shares of common stock on January 20, 2010.
"Sales of our custom soft lens category increased significantly in the second quarter as our C-Vue Advanced Toric Multifocal lenses continue to gain traction in the marketplace, almost completely offsetting declines in our disposable lens category," observed Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "The C-Vue Advanced Toric Multifocal was introduced in the first quarter of Fiscal 2010 with a free trial option, and sales have increased as eye care professionals convert trial fits to revenue-generating sales. We expect a similar phenomenon over time with our recently introduced C-Vue Advanced® HydraVUE™ line of silicone hydrogel custom contact lenses for monthly replacement, which are completely customizable and feature a risk-free trial program and exceptional deliverability."
"Although sales and royalties were lower than prior-year levels in the second quarter, we are encouraged that the 1.5% decline in our specialty contact lens sales represented an improvement relative to a 9.2% decrease in the first quarter, while the 4.8% decline in royalty income was much less severe than the 14.0% first quarter decrease. Longer-term, we believe that the specialty segment of the contact lens market will benefit significantly as the presbyopic population continues to grow at a faster rate than America's population as a whole, and we have positioned our Company to benefit from such trends by providing independent practitioners with specialty contact lens options that contribute to patient retention and practice profitability," concluded Pecora.
For the six months ended December 31, 2010, net sales including royalty income decreased 7% to approximately $4.3 million, compared with approximately $4.6 million in the first half of FY2010. The decrease in revenue was primarily due to a 5.7% decline in sales of the Company's various types of specialty contact lenses and a 9.4% decline in royalty income.
Pretax income decreased 29.8% to $1,013,823 in the six months ended December 31, 2010, compared with $1,444,801 in the prior-year period. The decrease in pretax income was primarily attributable to lower sales and royalty income and an increase in interest expense related to the Company's loan with Regions Bank, partly offset by a modest reduction in SG&A expenses.
The Company reported net income of $682,086 for the first half of FY2011, a decrease of 25.8% when compared with net income of $919,396 in the corresponding period of the previous fiscal year. The Company earned $0.29 per diluted share in the first six months of FY2011, which represented an increase of 45.0% when compared with earnings of $0.20 per diluted share in the first six months of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the six months ended December 31, 2010, versus 4,556,969 diluted shares in the prior-year period.
The Company recently declared its 18th consecutive quarterly cash dividend, in the amount of $0.09 per share of common stock outstanding. The amount and frequency of future dividends will depend upon earnings, cash flow, and other aspects of the Company's business as determined and declared by the Board of Directors.
About Unilens Vision Inc. -- "The Independent Eye Care Professionals' Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida and its wholly owned subsidiary Unilens Vision Sciences Inc. develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI."
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
UNILENS VISION INC.
SECOND QUARTER -- FISCAL 2011
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
(All figures in U.S. Dollars)
RESULTS OF OPERATIONS
Three Three
Months Months Six Months Six Months
Ended Ended Ended Ended
December December December December
31, 2010 31, 2009 31, 2010 31, 2009
---------- ----------- ----------- ----------
Revenues:
Sales $1,393,094 $ 1,414,539 $ 2,922,668 $3,098,212
Royalty income 715,603 751,386 1,375,809 1,519,062
---------- ----------- ----------- ----------
Total revenues 2,108,697 2,165,925 4,298,477 4,617,274
---------- ----------- ----------- ----------
Operating costs and
expenses:
Cost of sales 877,754 843,217 1,775,844 1,804,588
Expenses 641,056 672,989 1,367,875 1,376,198
---------- ----------- ----------- ----------
Total operating costs
and expenses 1,518,810 1,516,206 3,143,719 3,180,786
---------- ----------- ----------- ----------
Income from operations 589,887 649,719 1,154,758 1,436,488
---------- ----------- ----------- ----------
Other non-operating
items:
Other income 900 355 1,445 823
Remeasurement income - 1,288 - 1,823
Interest (expense)
income (71,128) 2,709 (142,380) 5,667
---------- ----------- ----------- ----------
Total other non-operating
items (70,228) 4,352 (140,935) 8,313
---------- ----------- ----------- ----------
Income before income tax
expense 519,659 654,071 1,013,823 1,444,801
Income tax expense 169,422 228,763 331,737 525,405
---------- ----------- ----------- ----------
Net income for the
period $ 350,237 $ 425,308 $ 682,086 $ 919,396
========== =========== =========== ==========
Net income per common
share:
Basic $ 0.15 $ 0.09 $ 0.29 $ 0.20
Diluted $ 0.15 $ 0.09 $ 0.29 $ 0.20
Weighted average shares
outstanding 2,369,354 4,557,852 2,369,354 4,556,969
========== =========== =========== ==========
CASH FLOWS
Provided (used) by:
Operating activities $ 495,440 $1,411,655
Investing activities (131,084) 239,876
Financing activities (1,026,484) (819,128)
----------- ----------
(Decrease) increase in cash $ (662,128) $ 832,403
=========== ==========
BALANCE SHEET June 30, December December
2010 31, 2010 31, 2009
----------- ----------- ----------
Cash and cash equivalents $ 1,080,540 $ 418,412 $2,262,852
Total assets 4,467,338 4,099,157 5,975,079
Current liabilities 2,519,513 2,378,192 1,181,462
Total liabilities 6,819,513 6,217,768 1,181,462
Stockholders' (deficit)
equity $(2,352,175) $(2,118,611) $4,793,617
=========== =========== ==========
For more information, please contact:
Leonard F. Barker
CFO
Unilens Vision Inc.
(727) 544-2531
len.barker@unilens.com
or
RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
info@rjfalkner.com
UVIC.. $03.09
Aththe current leveland new products on stream,, UVIC should trade higher in the next year.. While not a barn burner UVIC offers downside protection with it's dividend...
The interest here in the company really dried up quickly. The report wasnt bad, looks to me like they stopped losing sales.
The only thing im comfortable doing a DCF calclulation is my hewlett packard calc which is lost but Ill try and explain my reasoning whithout any hard numbers.
If you assume the royalty income continues in its present amount, it's about 2.8 million a year. Ill just say three.
So 3 mil for six years is 18 mil. Or less depending on the rate you use. The market value of the stock with the new share count is around 12.4 mil. And then theres about 4 mil of debt net of cash and recievables, inventory etc.
When the share repurchase was announced, I wondered how bausch and lomb missed that one. The royalty they pay alone would have been able to finance the stock purchase.
I guess what I was thinking was let the cash flows from the royalty finance the buyout and you get 6 million of annual revenues for very very cheap. Seems to me those numbers would jive for a bausch and lomb or a coopervision looking to grow revenues by aquisition.
OK I keep saying I haven't sat down and done a DCF so here is a link for anyone that is curious and you can plug in your own assumptions.
http://www.lasvegas4us.com/JwwDCF/discounted_cash_flow_calculator.htm
After plugging in a few things one thing I could see is perhaps Baker Street would try to get the company to liquidate its current business and sell the royalty? To me its not worth the risk for the upside at the levels they paid anyway.
I haven't sat down and done a DCF but I think there would have to be a non-trivial amount of royalty income in 2016 and beyond (when the last adjustment occurs to the royalty) for the present value of the royalty to be worth more then the current share price. Since I sold out my thinking was/is there is very little to nothing coming from the royalty when the patents end. So one is left with the underlying business which from the PR looked negative. I am not sure what Baker Street Capital sees perhaps they have more insight into the royalty or see something I am missing?
I sold half my position friday. Had a feeling it was Baker Street Capital that set the price at 4.60 and was buying anything and everything. Its now a twenty percent owner.
I was expecting the royalty income to increase at least. They are not making enough right now to even cover the dividend after paying down the principle on the note.
I wonder if someones intending to sell this comapany out. The present value of the royalty income out six and a half years is worth close to the value of the stock right now I imagine. Went looking for my financial calculator but it has dissappeared.
I got rid of my remaining shares today was hoping to hold for long term capital gains tax but the report scared me along with the fear the market will start discounting the royalty as it approaches its end.
Surprised the stock held up this well!
Unilens Vision Reports Third Quarter Operating Results
Nine-Month Diluted E.P.S. of $0.30 Compare With $0.28 in Prior-Year Period
On Friday May 28, 2010, 12:01 pm
LARGO, FL--(Marketwire - 05/28/10) - Unilens Vision Inc. (OTC.BB:UVIC - News) (TSX-V:UVI - News), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2010.
Royalty income for the quarter ended March 31, 2010 increased slightly to a third quarter record of $734,803, compared with $734,249 in the three months ended March 31, 2009. Sales of licensed products by the Company's licensee, Bausch & Lomb, continued to increase, resulting in higher royalty income.
Net sales excluding royalty income declined to $1,535,454 in the most recent quarter, versus $1,701,043 in the third quarter of FY2009. The decrease in sales was primarily due to a soft U.S. economy and increased competition from new product offerings and rebate programs.
FY2010 third quarter pretax income decreased 39.5% to $450,559, compared with $745,249 in the third quarter of FY2009. The decrease was primarily attributable to (1) a reduction in gross profit resulting from lower sales, (2) one-time administrative expenses of approximately $110,000 associated with stock compensation expense and the migration of the Company's corporate presence from Canada to the U.S., and (3) interest expense and amortization of loan fees of approximately $60,000 related to financing of the stock repurchase completed in January 2010.
After recording net income tax expense of $174,990, the Company reported net income of $275,569 in the most recent quarter, a decrease of 38.3% when compared with net income of $446,850 in the year-earlier quarter (after income tax expense of $298,399). The Company earned $0.10 per diluted share in the third quarter of FY2010, versus earnings of $0.10 per diluted share in the third quarter of FY2009. Diluted per-share earnings were calculated on 2,855,684 common shares in the FY2010 third quarter, versus 4,555,678 diluted shares in the prior-year quarter. The 37% decrease in average diluted shares resulted from the Company's repurchase of 2,188,861 outstanding shares of common stock on January 20, 2010.
"The decline in third quarter earnings was primarily due to the introduction of new products and marketing programs by certain competitors in the midst of an economic recession, combined with one-time administrative expenses," stated Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "We have developed strategies to address recent competitive challenges and will continue to build upon our reputation as 'The Independent Eye Care Professionals' Contact Lens Company'. Meanwhile, our royalty income stream continues to grow as Bausch & Lomb utilizes our proprietary technology in new products and markets its contact lenses in an expanding number of countries around the world."
Royalty income for the nine months ended March 31, 2010 increased 6.6% to a record $2,253,865, compared with $2,114,215 in the first nine months of FY2009, demonstrating continued sales growth of licensed products by Bausch & Lomb.
For the nine months ended March 31, 2010, net sales excluding royalty income declined to $4,633,666, compared with $4,992,811 in the corresponding period of the previous fiscal year. Net sales of the Company's C-Vue brand disposable contact lenses increased approximately 0.5% during the first nine months of FY2010, while sales of custom lenses and replacement products continued to decline, as expected.
Pretax income for the nine months ended March 31, 2010 decreased 10.6% to $1,895,360, compared with $2,120,225 in the prior-year period. After recording net income tax expense of $700,395, the Company reported net income of $1,194,965, for the nine months ended March 31, 2010, versus net income (after income tax expense of $848,063) of $1,272,162 in the first nine months of FY2009. The Company earned $0.30 per diluted share in the nine months ended March 31, 2010, versus earnings per diluted share of $0.28 in the prior-year period. Diluted per-share earnings were calculated on 3,998,122 common shares in the first nine months of FY2010, compared with 4,556,425 diluted shares in the corresponding period in FY2009. The 12% decrease in average diluted shares resulted from the Company's repurchase of 2,188,861 outstanding shares of common stock in January 2010.
About Unilens Vision Inc. -- "The Independent Eye Care Professionals' Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI".
(Note: All financial information in this release is stated in U.S. Dollars.)
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
UNILENS VISION INC.
THIRD QUARTER - FISCAL 2010
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
(All figures in U.S. Dollars)
RESULTS OF OPERATIONS
Three Three
Months Months Nine months Nine months
Ended Ended Ended Ended
March 31, March 31, March 31, March 31,
2010 2009 2010 2009
---------- ---------- ----------- ----------
Sales $1,535,454 $1,701,043 $ 4,633,666 $4,992,811
Cost of sales 912,581 943,931 2,717,169 2,752,561
---------- ---------- ----------- ----------
622,873 757,112 1,916,497 2,240,250
---------- ---------- ----------- ----------
Expenses 827,865 731,093 2,204,063 2,206,395
---------- ---------- ----------- ----------
(Loss) income from
operations (204,992) 26,019 (287,566) 33,855
Other items:
Royalty income 734,803 734,249 2,253,865 2,114,215
Other expense (16,059) (12,917) (15,236) (19,406)
Remeasurement expense (3,398) (2,479) (1,575) (11,463)
Interest (expense) income (59,795) 377 (54,128) 3,024
---------- ---------- ----------- ----------
655,551 719,230 2,182,926 2,086,370
---------- ---------- ----------- ----------
Income before income tax
expense 450,559 745,249 1,895,360 2,120,225
Income tax expense 174,990 298,399 700,395 848,063
---------- ---------- ----------- ----------
Net income for the
period $ 275,569 $ 446,850 $ 1,194,965 $1,272,162
========== ========== =========== ==========
Net income per common
share:
Basic $ 0.10 $ 0.10 $ 0.30 $ 0.28
Diluted $ 0.10 $ 0.10 $ 0.30 $ 0.28
========== ========== =========== ==========
CASH FLOWS
---------- ---------- ----------- ----------
Provided (used) by:
Operating activities $ 398,389 $ 960,719 $ 2,122,312 $2,255,774
Investing activities 237,343 (264,083) 477,219 (329,144)
Financing activities (1,559,953) (409,565) (2,691,349) (2,593,908)
---------- ---------- ----------- ----------
Increase (decrease) in
cash $ (924,221) $ 287,071 $ (91,818) $ (667,278)
========== ========== =========== ==========
========== ========== =========== ==========
BALANCE SHEET
---------- ----------- ----------
June 30, March 31, March 31,
2009 2010 2009
---------- ----------- ----------
Cash and certificates of
deposit $1,678,626 $ 1,085,233 $1,174,735
Total assets 5,749,661 4,552,449 5,529,389
Current liabilities 1,056,312 2,444,815 1,024,441
Total liabilities 1,056,312 7,044,815 1,024,441
Stockholders' equity
(deficit) $4,693,349 $(2,492,366) $4,504,948
========== =========== ==========
Unilens Vision Inc. Declares Quarterly Cash Dividend of $0.09 Per Share
On Tuesday May 4, 2010, 9:02 am
LARGO, Fla., May 4 /PRNewswire-FirstCall/ -- The Unilens Vision Inc. (OTC Bulletin Board:UVIC.ob - News) (TSX Venture Exchange:UVI.v - News) Board of Directors yesterday declared a quarterly cash dividend of $0.09 per common share, payable May 28, 2010 to stockholders of record at the close of business on May 14, 2010.
"We are pleased to continue the $0.09 per share quarterly dividend. This is our 15th consecutive quarterly dividend, which on a annualized dividend rate of $0.36 per share provides a dividend yield of 6.5% based on the closing price of our common stock on Friday April 30, 2010," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc.
About Unilens Vision Inc. – "The Eye Care Professionals Specialty Contact Lens Company"
Established in 1989, Unilens Vision Inc., a Delaware corporation, through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Len Barker CFO, Unilens Vision Inc. at (727) 544-2531
UVIC insider purchases get a mention on thestreet.com.
http://www.thestreet.com/_yahoo/story/10735962/1/two-chipotle-insiders-sell-81m-worth.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Another form 4 was filed today for more UVIC insider purchases! 103,852 shares were purchased in the last few days by Baker Street Capital Management!
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7200898-2238-16665&type=sect&TabIndex=2&companyid=122791&ppu=%252fdefault.aspx%253fcik%253d852564
A 10% owner of UVIC just added 24,804 shares to his position!
http://www.sec.gov/Archives/edgar/data/852564/000119380510001115/xslF345/e606831_ex.xml
The symbol has changed to UVIC. I'll request a change for the board.
Unilens Announces Change in Jurisdiction From British Columbia Canada to the State of Delaware
On Thursday April 1, 2010, 5:23 pm EDT
LARGO, Fla., April 1 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF, UVIC; TSX Venture Exchange: UVI) announced the change in domicile and the continuance of its Corporate existence from British Columbia Canada to the State of Delaware effective today. The continuation to Delaware, which was overwhelmingly approved by shareholders on March 25, 2010, does not result in any change in the business, assets, liabilities, net worth, or management of the Company.
"We are pleased that as an SEC registered Delaware corporation, our corporate governance will now be a matter of U.S. law, eliminating in some cases redundant and conflicting requirements between U.S. and Canadian jurisdictions," stated Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "Furthermore, we believe that trading as a U.S. issuer on the OTC Bulletin Board, rather than as a foreign private issuer may result in greater potential interest by investors, resulting in a more active market for our shares," concluded Mr. Pecora.
The Company's shares will continue to trade on the OTC Bulletin Board, utilizing the 4-digit symbol "UVIC" and on the TSX Venture exchange under the symbol "UVI".
About Unilens Vision Inc. – "The Independent Eye Care Professionals Contact Lens Company"
Established in 1989, Unilens Vision Inc., a Delaware corporation, through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker at (727) 544-2531
I saw some 99k share bids I think in the 4.7 to 4.8 range the past couple weeks wasn't sure they were "real" (i.e. someone really wanting to buy that many) but I guess it could have been them.
Baker St. Capital bought about 60000 shares over the past week at prices ranging from $4.78-4.90.
They now hold about 10% of the stock according to today's 13-D.
Baker Street Capital is a new 9.9% holder in UVICF.
http://www.sec.gov/Archives/edgar/data/852564/000092189510000428/sc13d00322uni_01202010.htm
Unilens Announces Annual General Meeting Results and Stock Option Grants
LARGO, Fla., March 26 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI) today announced that the shareholders of Unilens Vision Inc. voted in favor of all of the resolutions set out in the Company's Information Circular dated February 26, 2010, as recommended by management. The resolutions approved the continuation of the Company into the State of Delaware, a new incentive stock option plan, the election of Directors, and the appointment of Auditors. The Company expects to complete the continuation, which will change the Company's jurisdiction of origination from British Columbia, Canada to Delaware, in the coming weeks.
The Company has granted 160,000 options to ten people including employees and directors of the Company under the new incentive stock option plan effective March 25, 2010, all of which are exercisable at US $4.83 per share, being the closing price of the Company's shares on March 25, 2010.
About Unilens Vision Inc. – "The Independent Eye Care Professionals Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker at (727) 544-2531
SOURCE Unilens Vision Inc.
Timestamp:
March 26, 2010 09:16 EST
Contact Information:
Leonard F. Barker, +1-727-544-2531
WebSite:
http://www.unilens.com
Just got the proxy materials regarding the continuation in the mail today. Changing to a US corporation was in the back of mind this should be great to enhance long term value.
I dont quite understand the tax consequences. UVICF is my largest holding as well and this could pose a problem. Any CPAs follow this board and know any thing about these situations?
Management also wants a stock option plan. Cant say theyve done a bad job.... But.....
Andrew
My guess is they will not increase the dividend as they have debt to service but it could be possible. Maybe they might make a small dividend increase (e.g. 1-2 cents per quarter).
UVICF is my largest position too. Are you guys expecting an increase in the dividend this year?
UVICF..$4.60
Is my largest position and expect it to be 50% higher in 6 Mos..
I agree with mike that we will see a rqamp up in earnings starting with the next Qtr.. hank
This was a nice quarter for UVICF. Next quarter it should catch a lot of attention as the share count will be much, much lower which will increase earnings significantly.
Unilens Vision Reports Record Second Quarter Earnings And Royalty Income
Earnings Increase 18% To $0.09 Per Share
On Friday February 26, 2010, 12:32 pm EST
LARGO, Fla., Feb. 26 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter ended December 31, 2009 (FY2010).
Royalty income for the FY2010 second quarter increased 12.7% to a record second quarter of $751,386 compared with $666,569 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued royalty income growth.
Net sales excluding royalty income, were $1,414,539 in the FY2010 second quarter, 7.6% less than $1,530,242 reported in the previous year second quarter (FY2009). Â Sales of our C-Vue brand of disposable lenses sold exclusively to independent eye care practitioners which accounts for a significant portion of our sales, decreased slightly under 1%, while sales of our custom and replacement lenses declined, as expected.
FY2010 second quarter income before taxes increased 7.8% to a record second quarter $654,071 compared with $606,717 in the prior-year quarter. After recording net income tax expense of $228,763, Unilens reported net income of $425,308, an increase of 18.5% compared to the previous year quarter, or $0.09 per diluted share. In the FY2009 second quarter, the Company reported net income of $358,945, or $0.08 per diluted share, which included income tax expense of $247,772.
"We are pleased with our second quarter and six months results, considering the current economic environment," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Sales of our C-Vue brand of lenses sold exclusively to independent practitioners, combined with a 13% growth in royalty revenue derived from Bausch & Lomb's sales of multifocal lenses that use our key technologies, was responsible for our record second quarter performance."
"I am also pleased to report that the Unilens' Board of Directors declared its regular quarterly dividend of US $0.09 per common share, payable today. This decision was based on the Company's current balance sheet, and projected operating cash flows and is consistent with the Board's commitment that shareholders should share directly in the earnings achieved by management while continuing to execute our growth strategy."
Royalty income for the six months ended December 31, 2009 increased 10.1% to a record $1,519,062, compared with $1,379,966 in the prior-year six months, demonstrating continued demand for sales of licensed products by our licensee Bausch & Lomb. Â
For the six months ended December 31, 2009, net sales excluding royalty income were $3,098,212, 5.9% less as compared to $3,291,768 for the prior-year six months. Net sales of the Company's C-Vue brand disposable contact lenses increased approximately 3% during the first six months of fiscal year 2010, while sales of custom lenses and replacement products lines declined, as expected.
Income before taxes for the six months ended December 31, 2009 increased 5.1% to $1,444,801, compared with $1,374,976 in the prior-year six months. After recording net income tax expense of $525,405, Unilens reported net income of $919,396, or $0.20 per diluted share, for the six months ended December 31, 2009. This compared with net income of $825,312, or $0.18 per diluted share, in the prior-year six months of fiscal year 2009, which included net income tax expense of $549,664.
"I am also pleased with the Company's repurchase of 2,188,861 shares of its common stock announced on January 20, 2010, from Uniinvest Holding AG in Liquidation for an aggregate purchase price of $6,894,912 or $3.15 per share. We believe that the stock repurchase represents a very attractive use of our capital and reflects our commitment to building long-term shareholder value. Currently there are 2,369,354 shares of Company common stock outstanding," concluded Mr. Pecora.
About Unilens Vision Inc. – "The Independent Eye Care Professionals Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals.  Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
(Note: All financial information in this release is stated in U.S. Dollars.)
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. Â For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. Â The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531
UNILENS VISION INC.
SECOND QUARTER - FISCAL 2010
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
-------------------------------------------------------------------------
(All figures in U.S. Dollars)
RESULTS OF OPERATIONS
=========================================================================
Three Months Three Months Six Months Six Months
Ended Ended Ended Ended
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2009 2008 2009 2008
-------------------------------------------------------------------------
Sales $1,414,539 $1,530,242 $3,098,212 $3,291,768
Cost of sales 843,217 873,498 1,804,588 1,808,630
-------------------------------------------------------------------------
571,322 656,744 1,293,624 1,483,138
-------------------------------------------------------------------------
Expenses 672,989 703,341 1,376,198 1,475,302
-------------------------------------------------------------------------
(Loss) income from
operations (101,667) (46,597) (82,574) 7,836
Other items:
Royalty income 751,386 666,569 1,519,062 1,379,966
Other income (expense) 355 (9,074) 823 (6,489)
Remeasurement income
(expense) 1,288 (4,557) 1,823 (8,984)
Interest income 2,709 376 5,667 2,647
-------------------------------------------------------------------------
755,738 653,314 1,527,375 1,367,140
-------------------------------------------------------------------------
Income before income tax
expense 654,071 606,717 1,444,801 1,374,976
-------------------------------------------------------------------------
Income tax expense 228,763 247,772 525,405 549,664
-------------------------------------------------------------------------
Net income for the period $425,308 $358,945 $919,396 $825,312
=========================================================================
Net income per common
share:
Basic $0.09 $0.08 $0.20 $0.18
Diluted $0.09 $0.08 $0.20 $0.18
=========================================================================
CASH FLOWS
-------------------------------------------------------------------------
Provided (used) by:
Operating activities $529,528 $588,372 $1,411,655 $1,295,055
Investing activities 242,802 (32,461) 239,876 (65,061)
Financing activities (409,564) (409,564) (819,128) (2,184,343)
-------------------------------------------------------------------------
Increase (decrease)
in cash $362,766 $146,347 $832,403 $(954,349)
=========================================================================
=========================================================================
BALANCE SHEET
-------------------------------------------------------------------------
June 30, Dec. 31, Dec. 31,
2009 2009 2008
-------------------------------------------------------------------------
Cash and certificates of
deposit $1,678,626 $2,262,852 $640,143
Total assets 5,749,661 5,975,079 5,272,295
Current liabilities 1,056,312 1,181,462 804,632
Total liabilities 1,056,312 1,181,462 804,632
Stockholders' equity $4,693,349 $4,793,617 $4,467,663
=========================================================================
UVICF declares $.09/share dividend
(PR Wires) PRW: Unilens Vision Inc. Declares Regular Quarterly Cash Dividend
of U.S. $0.09 Per Share
PRW: Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09
Per Share
Quarterly Cash Dividend Provides an Annualized Yield of 8%
LARGO, Fla., Feb. 1 /PRNewswire-FirstCall/ -- The Unilens Vision Inc. (OTC
Bulletin Board: UVICF) (TSX Venture Exchange: UVI) Board of Directors today
declared its regular quarterly cash dividend of U.S. $0.09 per common share,
payable February 26, 2010 to stockholders of record at the close of business
on February 12, 2010.
"We are pleased to continue the U.S. $0.09 per share quarterly dividend,
which on a annualized dividend rate of U.S. $0.36 per share provides a
dividend yield of 8.2% based on the closing price of our common stock in the
U.S. on Friday January 29, 2010", stated Michael J. Pecora, Chief Executive
Officer of Unilens Vision Inc.
About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact
Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned
subsidiary Unilens Corp., USA, located in Largo, Florida, develops,
licenses, manufactures, distributes and markets contact lenses primarily
under the C-Vue brand directly to Independent Eye Care Professionals.
Additional information on the Company may be accessed on the Internet at
www.unilens.com. The Company's common stock is listed on the OTC Bulletin
Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange
under the symbol "UVI".
(Note: All financial information in this release is stated in U.S. Dollars.)
The information contained in this news release, other than historical
information, consists of forward-looking statements that involve risk and
uncertainties that could cause actual results to differ materially from
those described in such statements. For a discussion of certain factors
that could cause actual results to differ materially from those described in
the forward-looking statements, please refer to the Company's most recent
filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange
has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
For more information, please contact:
Len Barker CFO, Unilens Vision Inc. at (727) 544-2531
SOURCE Unilens Vision Inc.
/CONTACT: Len Barker, CFO, Unilens Vision Inc., +1-727-544-2531
/Web site: http://www.unilens.com
(
UVICF 2010 earnings should be awesome!
Just wait until earnings come out! My little baby of 3 years is finally getting to be a big winner.
Unilens Announces Closing of Stock Repurchase Agreement and Director Resignation
On Wednesday January 20, 2010, 4:00 pm
LARGO, Fla., Jan. 20 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI) today announced the Company completed the Stock Purchase Agreement announced on November 9, 2009, in which it repurchased 2,188,861 shares of its common stock, representing approximately 48% of it's outstanding shares, from its largest shareholder, Uniinvest Holding AG in Liquidation (Uniinvest) for an aggregate purchase price of US $6,894,912 or $3.15 per share.
The Company funded the transaction primarily through a draw of US $6.0 million against the $6.9 million 5-year term loan facility provided to the Company's wholly owned subsidiary Unilens Corp., USA, by Regions Bank. The loan facility was arranged by the Company's Investment Bankers, Hyde Park Capital Partners, LLC. The loan facility bears a floating interest rate of 30-day LIBOR plus 3.75% with a floor of 4.75%, and is secured by certain assets of the Company. The purchase price represents a discount of 25% to the closing price of our common stock in the US of $4.22 on Tuesday January 19, 2010.
Unilens has received and accepted the resignation of Ms. Elizabeth J. Harrison as a Director of the Company as of January 19, 2010. Ms. Harrison served as the Uniinvest representative on our Board of Directors since 2006. The Board of Directors and Management wish to thank Ms. Harrison for her service to the Company.
"We believe that the stock repurchase represents a very attractive use of our capital and reflects our commitment to building long-term shareholder value," stated Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "The transaction is highly accretive to earnings per share and eliminates any possible negative impact on our share value associated with the 48% stock overhang," concluded Mr. Pecora.
About Unilens Vision Inc. – "The Independent Eye Care Professionals Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Len Barker at (727) 544-2531
Hopefully it is just a bit of dyslexia (I do this type of thing way too much!) rather then (early) Alzheimers but I meant creditor's in this post (not debtors).
I was just rechecking the filing and they (creditors) have 30 days but the notice gives them 20. Its not clear if this is business days or calendar days since the legal print makes a distinction for "Business Day" and not the section for 30/20 days does not use the words "Business Day" I tend to think it is calendar days which would mean that this week it would be official.
Unilens Announces Extraordinary Meeting Results
On Tuesday December 22, 2009, 9:00 am
LARGO, Fla., Dec. 22 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI) today announced that the shareholders of Unilens Vision Inc. voted overwhelmingly in favor of the resolution to repurchase 2,188,861 of its shares at the extraordinary general meeting of its shareholders held yesterday. Of the 2,361,854 common shares eligible to be voted, 1,154,767 common shares (or 48.9%) were voted at the meeting with 1,141,138 (or 98.8%) voted in favor of the repurchase resolution.
About Unilens Vision Inc. – "The Independent Eye Care Professionals Contact Lens Company"
Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI".
The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Leonard F. Barker at (727) 544-2531
I honestly don't see them getting any more vocal. I've spoken to management (CEO 2x and CFO once) and I doubt they plan to change anything. I think the most likely long-term outcome is a management buy out. It makes the most sense.
I think you are right about them being more vocal next year.
Then we would be left with in the neighborhood of a 15% dividend yield (if we keep getting the bonus) not the worst thing in the world .
I got the impression that they may be a little more vocal in 2010 in terms of getting the word out about the company.
That is a risk and I agree it is small. I think the reason that someone wouldn't do that is because the purchase of the shares by UVICF is what will drive the price of UVICF north due to the increase in EPS. If someone else buys the shares the share price catalyst is gone.
I think the bigger (though not big) risk is that one of the debtors of the bankrupt fund sees the stock trading at a high premium (without realizing the illiquidity of such an amount of shares) and wants the shares. But the company characterized that as unlikely and I would think debtors in bankruptcy just want cash and not to mess around.
I have the same assessment of the vote. I just think that some people may be waiting for it to buy or may buy more on a positive vote.
I would be shocked if the vote isn't for especially since non-votes don't count though management can't vote either.
I noticed in the fine print the they would be reimbursed 500k if it doesn't go through under some reasons. I certainly hope that is a lot more then the actual costs for soliciting the proxies! Either way by Q2 we should be getting some very nice EPS numbers.
Appreciate your posts on GAXC's DVD business (I have no position but its good to keep up with what is happening there in case I take one).
I think there is a good chance of a bump up in share price on Monday or Tuesday as the proxy vote is on Monday.
I just voted my UVICF shares in favor of the repurchase of the Uniinvest UVICF holdings. I encourage anyone with shares to vote for the repurchase!
You can vote on the web at www.proxyvote.com.
Proxy Materials arrived.
I got mine in the mail today and certainly intend to vote in favor!
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
186
|
Created
|
06/29/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |